Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals
$ORIC
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $20.00 | Overweight | Wells Fargo |
| 9/6/2024 | $20.00 | Buy | Stifel |
| 2/23/2024 | Overweight | Cantor Fitzgerald | |
| 9/22/2023 | $8.00 | Outperform | Wedbush |
| 3/23/2023 | $16.00 | Neutral → Buy | H.C. Wainwright |
| 3/21/2023 | $15.00 | Neutral → Buy | Guggenheim |
| 3/16/2023 | $14.00 | Perform → Outperform | Oppenheimer |
| 7/18/2022 | Perform | Oppenheimer |
Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J
Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resis
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data on ORIC-944, a potent, highly selective, orally bioavailable allosteric inhibitor of PRC2, which demonstrated synergistic activity and improved progression-free survival (PFS) when combined with androgen receptor pathway inhibitors (ARPIs) in models of prostate cancer. "We are excited by the potential of
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2025 (the "Grant Date"), ORIC granted a total of 50,600 non-qualified stock options and 8,250 restricted stock units to three new non-executive employees who began their employment with ORIC in March 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stoc
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April: Needham's 24th Annual Healthcare Conference – Presenting a company overview on Monday, April 7, 2025, at 1:30 p.m. ETStifel 2025 Virtual Targeted Oncology Forum – Participating in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. ET Webcasts of the presentation and discussion will be available through the investor section of the company's webs
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
DEFA14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
S-8 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)